| Pharmaceutical Information |
| Drug Name |
Pembrolizumab |
| Drug ID |
BADD_D01700 |
| Description |
Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing S228P Fc mutation.[A18829] It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds.[F136] It was developed by Merck & Co and firstly approved for the treatment of metastatic malignant melanoma. This is the first approved therapy against PD-1.[A7624] It was approved firstly by the FDA on September 4, 2014.[L2954] Its approval in melanoma was extended to several countries such as Australia, Israel, Korea, Macau, the European Union and the United Arab Emirates.[A33350] On June 12, 2018, Pembrolizumab was approved for the treatment of cervical cancer under the status of accelerated approval.[L2955] |
| Indications and Usage |
|
| Marketing Status |
Prescription |
| ATC Code |
L01FF02 |
| DrugBank ID |
DB09037
|
| KEGG ID |
D10574
|
| MeSH ID |
C582435
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
53713-0048; 69497-0001; 75895-0136; 0006-3026 |
| Synonyms |
pembrolizumab | SCH-900475 | lambrolizumab | MK-3475 | Keytruda |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
1374853-91-4 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
